New EpiPen Competitor Approved by FDA

A new competitor for EpiPen has been approved by the U.S. Food and Drug Administration.

The emergency injection device to treat life-threatening allergic reactions is called Symjepi and is made by Adamis Pharmaceuticals Corp., the Associated Press reported.

Symjepi is meant to be a "low-cost alternative" to EpiPen and similar products, and Adamis wants to sell it for less than generic EpiPens, according to company spokesman Mark Flather.

EpiPens have soared in price in recent years, prompting concern from doctors and patients alike.

An exact price has not been set for Symjepi, which will be sold in pairs like EpiPen, the AP reported.

MedicalNews
Copyright © 2017 HealthDay. All rights reserved.

Subscribe to MedicineNet's Allergy and Asthma Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors